the impact of metformin on cardiac troponin-i and st resolution in patients with st elevation myocardial infarction undergoing thrombolytic therapy

Background: thrombolytic therapy is a key in the management of st elevated myocardial infarction (stemi). metformin implies a series of cardioprotective effects. we aimed to investigate how pretreatment with metformin could affect cardiac troponin i (ctni) levels following reteplase therapy amid stemi patients. methods: a pilot randomized clinical trial was carried out in 80 stemi patients undergoing thrombolytic therapy with reteplase. the metformin group (n = 40) received a single dose of 1000 mg metformin orally before receiving reteplase, while the control group (n = 40) received only reteplase. the serum level of ctni was measured at baseline, 8, 16, 24, and 32 hours after the admission to assess myocardial damage. results: there was no significant difference in ctni levels at baseline (p = 0.657), 8 (p = 0.93), 16 (p = 0.690), 24 (p = 0.217), and 32 (p = 0.517) hours after stemi diagnosis between two groups. the mean differences were also not significant for changes of ctni at baseline and other time frames. conclusion: the results of the present study demonstrated that early use of 1000 mg metformin prior to reteplase could not reduce the level of ctni in stemi patients.